First Tracks Biotherapeutics (NASDAQ:TRAX) Earns Outperform Rating from Analysts at Wedbush

Analysts at Wedbush initiated coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX) in a report released on Friday. The brokerage set an “outperform” rating and a $30.00 price target on the stock. Wedbush’s price target indicates a potential upside of 51.07% from the company’s previous close.

TRAX has been the subject of a number of other reports. JPMorgan Chase & Co. assumed coverage on First Tracks Biotherapeutics in a research report on Thursday. They set an “overweight” rating and a $31.00 price target for the company. Barclays started coverage on First Tracks Biotherapeutics in a research report on Wednesday. They set an “overweight” rating and a $40.00 target price for the company. UBS Group began coverage on First Tracks Biotherapeutics in a report on Tuesday. They set a “buy” rating and a $45.00 price objective for the company. Finally, Leerink Partners began coverage on First Tracks Biotherapeutics in a report on Friday. They set an “outperform” rating and a $46.00 price target on the stock. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, First Tracks Biotherapeutics currently has a consensus rating of “Buy” and a consensus price target of $38.40.

First Tracks Biotherapeutics Trading Up 5.2%

TRAX stock opened at $19.86 on Friday. First Tracks Biotherapeutics has a 52-week low of $14.79 and a 52-week high of $26.80.